AGL 23.00 Decreased By ▼ -1.35 (-5.54%)
AIRLINK 104.95 Increased By ▲ 1.95 (1.89%)
BOP 5.67 Decreased By ▼ -0.04 (-0.7%)
CNERGY 3.88 Decreased By ▼ -0.08 (-2.02%)
DCL 8.35 Decreased By ▼ -0.15 (-1.76%)
DFML 41.92 Decreased By ▼ -1.07 (-2.49%)
DGKC 88.80 Decreased By ▼ -0.10 (-0.11%)
FCCL 22.77 Increased By ▲ 0.07 (0.31%)
FFBL 40.60 Increased By ▲ 2.40 (6.28%)
FFL 8.95 Decreased By ▼ -0.16 (-1.76%)
HUBC 161.89 Decreased By ▼ -1.81 (-1.11%)
HUMNL 11.53 Decreased By ▼ -0.27 (-2.29%)
KEL 4.81 Decreased By ▼ -0.04 (-0.82%)
KOSM 4.09 Decreased By ▼ -0.04 (-0.97%)
MLCF 38.75 Increased By ▲ 0.34 (0.89%)
NBP 53.30 Increased By ▲ 0.45 (0.85%)
OGDC 131.75 Decreased By ▼ -1.14 (-0.86%)
PAEL 25.32 Decreased By ▼ -0.33 (-1.29%)
PIBTL 6.28 Decreased By ▼ -0.10 (-1.57%)
PPL 119.20 Decreased By ▼ -0.30 (-0.25%)
PRL 23.97 Decreased By ▼ -0.63 (-2.56%)
PTC 12.96 Increased By ▲ 0.32 (2.53%)
SEARL 59.53 Decreased By ▼ -0.07 (-0.12%)
TELE 7.40 Decreased By ▼ -0.09 (-1.2%)
TOMCL 35.40 Increased By ▲ 0.25 (0.71%)
TPLP 8.71 Decreased By ▼ -0.14 (-1.58%)
TREET 15.86 Increased By ▲ 0.06 (0.38%)
TRG 56.90 Decreased By ▼ -1.00 (-1.73%)
UNITY 34.85 Decreased By ▼ -0.04 (-0.11%)
WTL 1.22 No Change ▼ 0.00 (0%)
BR100 8,537 Decreased By -7.8 (-0.09%)
BR30 27,304 Decreased By -87.5 (-0.32%)
KSE100 80,085 Increased By 92.2 (0.12%)
KSE30 25,540 Decreased By -4.4 (-0.02%)

LAHORE: Getz Pharma manufactures safe and efficacious medicines in its WHO, PIC/s, and EAEU pre-qualified manufacturing facility, a spokesman of the company, said.

Responding to false information about its product Risek IV 40 mg injection on electronic and social media, the spokesman said. “On February 12, 2024, the Federal Inspector of Drugs-IV, while conducting market surveillance in Moro, Sindh, identified counterfeit Risek 40mg IV injections at the premises of M/s Qalanari Medicos on Hospital Road, Moro, Nowsheroferoz.

Samples were sent for testing, including confirmation by Getz Pharma. We confirmed the sample as counterfeit, not manufactured by us, and provided a comparative analysis report to authorities, urging action.”

Getz Pharma condemns the misreporting by the electronic media of the Alert issued by Drug Regulatory Authority of Pakistan (DRAP) as if our manufactured product was deemed spurious or counterfeit, requiring recall.

Copyright Business Recorder, 2024

Comments

Comments are closed.